Evotec/$EVO
1D1W1MYTD1Y5YMAX
Capital at risk
About Evotec
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.
- Ticker
- $EVO
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 4,461
- Headquarters
- Hamburg, Germany
- Website
- www.evotec.com
Evotec Metrics
BasicAdvanced
$628M
-
-$1.29
1.26
-
Price and volume
Market cap
$628M
Beta
1.26
52-week high
$4.27
52-week low
$1.74
Average daily volume
60K
Financial strength
Current ratio
2.333
Quick ratio
2.023
Long term debt to equity
62.25
Total debt to equity
71.497
Profitability
EBITDA (TTM)
-84.946
Gross margin (TTM)
8.46%
Net profit margin (TTM)
-27.47%
Operating margin (TTM)
-20.33%
Effective tax rate (TTM)
-7.21%
Revenue per employee (TTM)
$185,720
Management effectiveness
Return on assets (TTM)
-5.39%
Return on equity (TTM)
-26.08%
Valuation
Price to revenue (TTM)
0.378
Price to book
0.81
Price to tangible book (TTM)
1.51
Price to free cash flow (TTM)
-1.559
Free cash flow yield (TTM)
-64.16%
Free cash flow per share (TTM)
-1.136
Growth
Revenue change (TTM)
-7.72%
Earnings per share change (TTM)
26.46%
3-year revenue growth (CAGR)
-3.51%
10-year revenue growth (CAGR)
17.08%
3-year earnings per share growth (CAGR)
23.85%
10-year earnings per share growth (CAGR)
39.61%
What the Analysts think about Evotec
Analyst ratings (Buy, Hold, Sell) for Evotec stock.
Analyst projections of the future price of Evotec stock.
Bulls say / Bears say
Evotec targets an adjusted EBITDA margin above 20% by 2028, ahead of the 18.7% consensus, underscoring a clear path to improved profitability. (Reuters)
Evotec reported Q2 2026 group revenues of €143.50 million and highlighted “growing commercial momentum,” demonstrating resilience and scale in its fee-for-service business. (Reuters)
Evotec and Odyssey Therapeutics entered an AI-enabled R&D collaboration in autoimmune and inflammatory diseases, potentially unlocking high-margin milestone payments and expanding its strategic partnership pipeline. (Reuters)
Evotec cut its FY 2026 guidance to €570–€610 million in group revenues (from €700–€780 million) and now forecasts an adjusted EBITDA loss of €70–€105 million (vs prior profit of up to €40 million), reflecting delayed milestone payments and weakening near-term earnings visibility. (Reuters)
TD Cowen downgraded Evotec to "hold" from "buy" and cut its price target to €4 from €7, citing customer delays in pharma partnership deals that are clouding its revenue growth outlook. (Reuters)
Activist investor MAK Capital, holding around 7% of Evotec, demanded the carve-out and U.S. IPO of its Just – Evotec Biologics division, accelerated restructuring and a board seat, signalling governance risk and shareholder frustration over five years of underperformance. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 21 Aug 2026.
Evotec Financial Performance
Revenues and expenses
Evotec Earnings Performance
Company profitability
Upcoming events
No upcoming events
Evotec News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.